Macular Degeneration Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- You are 65 years of age or older
- You have been diagnosed with dry age-related macular degeneration (AMD) affecting both eyes
- Your vision (when measured with corrective lenses using a standard eye chart) falls within a specific range — roughly between being able to see 1/10th and 4/10th of what someone with normal vision can see (confirm with trial site)
- You do not have any other significant eye conditions (such as glaucoma or a lazy eye) or serious health conditions that could affect how results are measured
- You are willing and able to sign a consent form agreeing to take part
Who may not be able to join:
- You are under 65 years of age
- You are currently pregnant
- You have previously had an inflammatory or infectious condition affecting your eyes
- You have a history of eye injury, diabetes, or any condition that could potentially damage your vision, even if your eyesight seems fine right now
- You have previously received injections of medication directly into your eye (known as intravitreal treatments)
- You are not willing to sign the consent form
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Maria Cristina savastano, Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Phone: +390630155701
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Autofluorescence atrophy area changes in treated eyes compared with sham group; Autofluorescence atrophy area changes in treated eyes compared with sham group (1)
Can't join this trial?
Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.